(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification Number) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Exhibit No. | Description | |||||||
99.1 | — | |||||||
EX-104 | — | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
Lexicon Pharmaceuticals, Inc. | ||||||||
Date: July 30, 2021 | By: | /s/ Brian T. Crum | ||||||
Brian T. Crum | ||||||||
Vice President and General Counsel |
Cover |
Jul. 30, 2021 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Document Period End Date | Jul. 30, 2021 |
Entity Registrant Name | Lexicon Pharmaceuticals, Inc. |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 000-30111 |
Entity Tax Identification Number | 76-0474169 |
Entity Address, Address Line One | 2445 Technology Forest Blvd., 11th Floor |
Entity Address, City or Town | The Woodlands |
Entity Address, State or Province | TX |
Entity Address, Postal Zip Code | 77381 |
City Area Code | 281 |
Local Phone Number | 863-3000 |
Title of 12(b) Security | Common Stock, par value $0.001 |
Trading Symbol | LXRX |
Security Exchange Name | NASDAQ |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Entity Emerging Growth Company | false |
Entity Central Index Key | 0001062822 |
Amendment Flag | false |
E!]9-
M$\-I[%NX B888;3INX!Z(<[5/[%S!]@Y.2:SI(9A*(=FSN4=.+P_/[W.ZQ;&
M)9).87Z5C*!3P!6[3'YKUIOM(^OJJN9%=5\TU99S<9O/P\?D^L/O*FR]-COS
MCXTO@ET+O_Y%]P502P,$% @ ?3[^4IE
M-8?20$3;8T.P6BP^0"X99K>]9!:G$!K\L
M?R5S'N8&LE6+A2M-=)* #\VM#I_/2,H,>6$RY^1GO^W[:/JJ[8+BEKXP+!)J
M3>:OR5++6D9
!9)?,M.[GAODOQ=:3EN#;\?@,1#;\SS,#!? DA.*;4%M;&J>XG!3!9_3
M*FU]'@=3I)+U+&[Z&-A\71BTI*)>>8#L0)SXB8Q3IBTH^;VX3^IJ[9@371B&
M13&C!K"?JCN8F2K#1*&FJSFZP6U:VMH7$Q^HC[[T&+:2&T%NS_SMD_5.^[
M?B"@=P<@^9U+[^?2JY,0U=4]CW(/ZR:UL*8Q%SORK-U1F*(K3-<\@V;1?*P2
M15ELD+ZSZ3)LVF&31G$,XF88^\ZS2_-LXY)G%4M0RBC@J:9SB:P<,Z$Y6*>V
MY]A"6$0'GC4-3#134PS[ATS[%LR'>XW=C'O7,H4M R%1VA
NQ$PZ&?R'0F)/4#RH7M5UMEHWQ0/BRC
M^G 41%,19]M\'63N7/C=!U[W.7 O'4Y8,CZVRIA_CN3;G,
H:N\PHF4>W\@L)^B7GO$1BRV]P->R-4:E=
MII(THRCGO&HL B8?)KEUS>_57+))D*LFS('9C-/;3>Z[&?BA-Q2;ES<4]R^I
M-V(G CNQ8*=@/H*NK;+@G$V34N7YKS%^6GQ2E\JQ:Z1BB&B9T$56Z8%(QD&:
MG2>T 57R!ZOE T*[EZBQ$P&*R=__Q.6"BY':8>XIP";8N+@@BI?]V7CZZV[O
M1I1VB*Y=3K>.S@48E\EX-4[$ [4XV('
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MK:Q5VIKIIU94?D#&V37GX=
FS%^/T(W>6R&O!)8-4Y4? 'WLEN!*^@:S9$UL2GH@YLOF&:
MF((2K27+6PV70M874)*VT@NOY;]:4K&206%J7H&MZ@CP1*V)7(/^1FI0#:'P
M'J_+"4*V&JQNA-2(O\CMRQ'-Y_.@L_EY:%>]E:!$NY%XM1P.C^T11S%.(K]3
MA1>\R^W8$.-*$T[A&-_F#0^\?Q'#OK?'Q3#PCH_!&5- _;5X" I@MG,A#B-C
MX>4@U&LD>\![]M@_X5QH9\5*>EG3,%Z*G<"(;!+9D,D5E,/J/-N'%\;%_65$
M4BFJO\Q6T$C1@-0,U--=<@8V$LJ%9S<*#Q/\LR*Y;R(9(,\&ULU9QK
M;]LX%H:_]U=H/5]V@6%-4=2%19M!-],.BLVT19.B@UTL#%X3H;84R$J3_/LE
M93N1;,D6)5O5?DD&ULU9I=;]NX$H;O\RN\WMO#F*1(D0R:+'*R[2+8=!NT
M671Q;@1^#&.ALF302N/\^S-2DMTF:;M"+"#JC3]D2C-\Y_%X9JQ7OVQ7U>PS
MI$W9U(=SMD_G,ZA]$\KZ\G#^Y\4;HN>_'.WMO?J)D+_^^_YL]FOCKU90M[.3
M!+:%,+LNV^7L8X#-IUE,S6KVL4F?RL^6D*/^I)-F?9/*RV4[XY2SQY^F VJ]
M"ISEA&72$P&9)T8I12P%[20^9AK^&!T6/@G/,9\OH0320"OMWYIZTOHI_726^>!YR3/
MJ23"XX-56/!ZXT-NO%0,Z(A)X$O;PTB8\.1R9T%?&(B/Z'P+]4FS6EW5=X.U
M3>&<\M%)W+Z1#.L:+8@3,N)^=$:CH1J,&H&(KQH?AL2$QY6[2_K22:*I2E^V
MF.#>8BN<2EL5AF.%:S"G114MUCBY[#H<#*8-/J#[N1)C_&7^U/(P&B8\F=Q1
MS!=&X3Q!QS'4'OK[/[K;B-*[B'X40CDNC+1$6=I-0R(CCC)/;":8!\4RRL"TR,#(Q,#"TR,#(Q,#&UL4$L! A0#% @ ?3[^4E6\YR*K!@ :#$ !4 ( !
M;R$ &QX